Eric Poer, an internationally-recognized forensic accounting, investigations, and disputes expert, led the forensic accounting and data analytics team retained to support A&O Shearman in conducting an independent investigation into Wells Fargo’s sales practices—an inquiry launched in response to one of the most significant financial consumer fraud scandals in U.S. history.
Robert Miś Provided Pivotal Expert Findings in a DOJ Landmark $577M Crypto Fraud Prosecution
Director Robert Miś was engaged by the US Department of Justice (DOJ) as its cryptocurrency-mining and blockchain technology expert in a landmark prosecution involving a $577 million cryptocurrency fraud scheme, described as the largest fraud ever prosecuted in the Western District of Washington.
A team of Secretariat experts helped Lockheed Martin recover more than $131 million in damages from the United States Air Force in an ASBCA hearing (Appeal of Lockheed Martin, ASBCA No. 62209) arising out of Lockheed Martin’s performance of the Air Force’s C-5 Reliability Enhancement and Re-engineering Program.
Supporting ISED Canada’s Successful 5G Wireless Spectrum Auction
On November 23, 2023, Innovation, Science, and Economic Development (ISED) Canada concluded its auction of spectrum licenses in the 3800 MHz band, which is an important band for 5G wireless service. The auction used a clock auction format with intra-round bidding to allocate thousands of spectrum licenses. The design followed a two-stage process in which generic licenses were allocated in the first stage, and then specific frequencies were assigned in a subsequent assignment stage.
Valuation of a Classic Fictional Character
Secretariat determined the valuation of a fictional character with a long-term presence in books, film, and theme parks. We provided our client with a reliable and unbiased valuation by conducting multiple independent analyses, each resulting in a valuation consistent with one another.
Biopharmaceutical Reasonable Royalties on Trial
When our client, a biopharmaceutical company, had exclusively licensed a patent for a novel type of cancer immunotherapy, a competitor undertook substantial efforts to be first to market for its lead indication despite being aware of potential infringement claims against its therapy. Upon the competitor achieving FDA approval, our client filed patent infringement claims. After an eight-day trial, the jury returned a verdict in favor of our client with a damages award that precisely matched the trial testimony.